{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Remmers S"],"funding":["NCI NIH HHS","Movember Foundation"],"pagination":["126-133"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9257656"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["41"],"pubmed_abstract":["<h4>Background</h4>Active surveillance (AS) is a management option for men diagnosed with low-risk prostate cancer. Opinions differ on whether it is safe to include young men (≤60 yr) or men with intermediate-risk disease.<h4>Objective</h4>To assess whether reasons for discontinuation, treatment choice after AS, and adverse pathology at radical prostatectomy (RP; N1, or ≥GG3, or ≥pT3) differ for men ≤60 yr or those with European Association of Urology (EAU) intermediate-risk disease from those for men >60 yr or those with EAU low-risk disease.<h4>Design setting and participants</h4>We analyzed data from 5411 men ≤60 yr and 14 959 men >60 yr, 14 064 men with low-risk cancer, and 2441 men with intermediate-risk cancer, originating from the GAP3 database (21 169 patients/27 cohorts worldwide)"],"journal":["European urology open science"],"pubmed_title":["Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative."],"pmcid":["PMC9257656"],"funding_grant_id":["P30 CA008748"],"pubmed_authors":["Beckmann K","Auvinen A","Patil D","Semjonow A","Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium","Guo W","Olivier J","Gnanapragasam V","Benfante N","Helleman J","Han Lin C","Lehmann K","Hayen A","Peter van Hooft","Denton B","Hirama H","Ferrante S","Mamedov A","Sugimoto M","Hugosson J","Rancati T","Kouspou M","van der Linden W","Logothetis C","Park L","Paich K","Dasgupta P","Suk Lee K","Crump T","Lofgren A","Hefermehl L","van der Kwast T","Lui Shiong L","Filson C","van Bochove K","Carroll P","Bjartell A","Robert G","Roobol MJ","Stavrinides V","Ha Chung B","Hyndman ME","Morgan TM","Trock B","Moore CM","Ruwe B","Remmers S","Bangma CH","Hulsen T","Kimberly-Duffell J","Roobol M","Klotz L","Pickles T","Bangma C","Van Hemelrijck M","Rannikko A","Rubio-Briones J","Hyndman E","Boutros P","Steyerberg E","Nieboer D","Ehdaie B","Elhage O","Villers A","LaPointe V","Cusick T","Haider M","Cowan J","Shiong Lee L","Frydenberg M","Perry A","Jenster G","Stricker P","Ahlgren H","Mascaros J","Morgan T","Moore C","Santaolalla A","Valdagni R"],"additional_accession":[]},"is_claimable":false,"name":"Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative.","description":"<h4>Background</h4>Active surveillance (AS) is a management option for men diagnosed with low-risk prostate cancer. Opinions differ on whether it is safe to include young men (≤60 yr) or men with intermediate-risk disease.<h4>Objective</h4>To assess whether reasons for discontinuation, treatment choice after AS, and adverse pathology at radical prostatectomy (RP; N1, or ≥GG3, or ≥pT3) differ for men ≤60 yr or those with European Association of Urology (EAU) intermediate-risk disease from those for men >60 yr or those with EAU low-risk disease.<h4>Design setting and participants</h4>We analyzed data from 5411 men ≤60 yr and 14 959 men >60 yr, 14 064 men with low-risk cancer, and 2441 men with intermediate-risk cancer, originating from the GAP3 database (21 169 patients/27 cohorts worldwide)","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-04-19T22:12:50.858Z","creation":"2022-07-20T06:36:21.784Z"},"accession":"S-EPMC9257656","cross_references":{"pubmed":["35813247"],"doi":["10.1016/j.euros.2022.05.012"]}}